Oral Mucositis Market expected to rise | Companies- Galera Therapeutics, Soligenix, Izun Pharma, MitoImmune Therapeutics, Tosk, Cellix Bio, Enzychem Lifesciences, Monopar Therapeutics

The Oral mucositis market report provides real-world prescription pattern analysis, emerging drugs assessment, market share, and uptake/adoption pattern of individual therapies, as well as historical and forecasted Oral mucositis market size from 2020 to 2034 in 7MM. The report also covers current Oral mucositis treatment practices/algorithms and unmet medical needs to curate the best opportunities and assess the market's underlying potential.
The Oral Mucositis market growth is driven by factors like increase in the prevalence of Oral Mucositis, investments in research and development, entry of emerging therapies during the study period 2020-2034.

The Oral Mucositis market report [https://www.delveinsight.com/report-store/oral-mucositis-om-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr] also offers comprehensive insights into the Oral Mucositis market size, share, Oral Mucositis epidemiology, emerging therapies, market drivers and barriers, ongoing clinical trials, key collaboration in the space, market uptake by key therapies and companies actively pushing Oral Mucositis market size growth forward.

Some of the key highlights from the Oral Mucositis Market Insights Report:

*
Several key pharmaceutical companies, including Galera Therapeutics, Soligenix, Izun Pharma, MitoImmune Therapeutics, Tosk, Cellix Bio, Enzychem Lifesciences, Monopar Therapeutics, and others, are developing novel products to improve the Myelodysplastic Syndrome treatment outlook.

*
Among the 7MM, the United States holds the largest market share for oral mucositis treatments in 2023.

*
Current treatment strategies for oral mucositis include general oral care protocols, measures to reduce mucosal toxicity from chemotherapy drugs, mouthwashes with mixed action, immunomodulatory agents, topical anesthetics, antiseptics, mucosal barriers and coating agents, cytoprotectants, mucosal cell stimulants, psychotherapy, and analgesics.

*
Available treatment options include Wecare's Oralcare rinse and gel, palifermin, episil, MuGard, acyclonine MUM, and others.

*
In August 2023, the US FDA issued a Complete Response Letter (CRL) for avasopasem manganese for the treatment of radiotherapy-induced severe oral mucositis. The CRL indicated that the results from the Phase III ROMAN trial were not sufficiently compelling to establish substantial evidence of the drug's effectiveness and safety. The company plans to request a Type A meeting with the FDA to understand the reasoning behind the decision and discuss potential next steps for a resubmission of the New Drug Application (NDA).

*
Additionally, in March 2023, the FDA granted fast-track designation to RRx-001 for the prevention and mitigation of severe oral mucositis caused by chemotherapy and radiation in patients with head and neck cancer.

*
The total Oral Mucositis market size will include the market size of the potential upcoming therapies and current treatment regimens in the seven major markets.

*
As per DelveInsight analysis, the Oral Mucositis market is anticipated to witness growth at a considerable CAGR

Strategise your business goals by understanding market dynamics @ Oral Mucositis Market Landscape [https://www.delveinsight.com/sample-request/oral-mucositis-om-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]

Oral Mucositis Overview

Oral mucositis (OM) is a debilitating condition characterized by inflammation, swelling, and ulcerations of the oral mucosa. It typically occurs when cancer treatments, such as chemotherapy or radiation, damage the rapidly dividing epithelial cells lining the gastrointestinal tract, leaving the mucosal tissue vulnerable to ulceration and infection. Common symptoms include a red, shiny, or swollen mouth and gums; sores on the mouth, gums, or tongue; pain or soreness in the mouth or throat; difficulty swallowing or speaking; a dry mouth; mild burning or pain while eating; soft, whitish patches or pus in the mouth or on the tongue; and increased mucus or thicker saliva.

Diagnosis of oral mucositis is primarily based on the appearance, location, and timing of oral lesions, along with the patient's medical history, which may indicate a treatment regimen linked to OM. Useful laboratory tests to confirm the diagnosis and identify the cause-especially if infections (fungal, bacterial, or viral) are suspected-include complete blood count (CBC), viral cultures, biopsy, and fungal testing.

Management of oral mucositis involves several approaches: nutritional support, pain control, oral decontamination, dry mouth palliation, and targeted therapeutic interventions. Treatment may include the use of topical agents, analgesics, mucosal protectants, and other therapies like interventions to reduce chemotherapy-induced mucosal toxicity, mouthwashes, immunomodulatory agents, topical anesthetics, mucosal barriers, and cytoprotectants. Rinsing the mouth with non-medicated solutions, such as saline water, sodium bicarbonate, or a combination of both, is recommended every four hours to help soothe the mucosal tissue and reduce irritation.

Do you know the treatment paradigms for different countries? Download our Oral Mucositis Market Sample Report [https://www.delveinsight.com/report-store/oral-mucositis-om-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]

Oral Mucositis Epidemiology Insights

*
According to the Oral Cancer Foundation (2022), oral mucositis (OM) is one of the most common and debilitating complications of cancer treatments, especially chemotherapy and radiation.

*
Studies show that oral mucositis affects approximately 30% to 40% of the general cancer patient population.

*
Additionally, research indicates that women are at a significantly higher risk of developing oral mucositis compared to men.

Oral Mucositis Epidemiology Segmentation

DelveInsight's Oral Mucositis market report is prepared on the basis of epidemiology model. It offers comprehensive insights to the Oral Mucositis historical patient pools and forecasted Oral Mucositis patients. The report provides in-depth data of various subtypes and for the same epidemiology is segmented further. The Oral Mucositis Market report proffers epidemiological analysis for the study period 2020-32 in the 7MM segmented into:

*
Oral Mucositis Prevalence

*
Age-Specific Oral Mucositis Prevalence

*
Gender-Specific Oral Mucositis Prevalence

*
Diagnosed and Treatable Cases of Oral Mucositis

Visit for more @ Oral Mucositis Epidemiological Insights [https://www.delveinsight.com/sample-request/oral-mucositis-om-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]

Oral Mucositis Treatment Market

Oral mucositis (OM) is a common and often debilitating side effect experienced by cancer patients undergoing anticancer treatments, especially chemotherapy and radiation. The management of this condition can be challenging for both patients and oncologists. While uncomplicated cases of mucositis are usually self-limiting, symptom management and supportive care are often sufficient. For mild to moderate mucositis pain, solutions like normal saline or sodium bicarbonate mouthwashes are effective, providing relief while being safe, inexpensive, and easy to use. These mouthwashes are particularly useful in managing chemotherapy-induced mucositis and can also be applied in cases of radiation-induced mucositis. Additionally, mouthwashes containing the tricyclic antidepressant doxepin have shown effectiveness for radiation-induced mucositis. In patients treated with mTOR inhibitors, dexamethasone mouthwashes have been found to reduce both the incidence and severity of mucositis with minimal side effects.

Several treatments are currently available on the market to manage oral mucositis. These include:

- Palifermin (recombinant human keratinocyte growth factor-1), which reduces the incidence of severe oral mucositis (Grade 3 and 4) in patients with hematologic malignancies.

- Wecare's Oralcare Rinse, which aids in healing and repairing the oral mucosa.

- Sodium fluoride, which offers increased protection against cavities.

- Xylitol, which promotes saliva production.

- Acyclonine MUM by RAM Pharma, a dental powder used for managing acute and chronic oral mucosal ulcerations, oral mucositis, aphthous ulcers, and trauma-induced lesions.

- MuGard, a mucoadhesive oral wound rinse designed for treating oral wounds, such as mucositis, stomatitis, traumatic ulcers, and aphthous ulcers.

- Episil, which provides immediate relief, typically within five minutes of application.

The oral mucositis market is expected to experience significant growth in the coming years, driven by the rising incidence of cancer and the anticipated introduction of new therapies during the forecast period (2024-2034). Key industry players, such as Galera Therapeutics and EpicentRx, are actively developing new treatments for oral mucositis and are evaluating their candidates in various stages of clinical development.

Among the seven major markets (7MM), the United States is expected to account for the largest share of the oral mucositis market in 2023.

Emerging therapies, including Avasopasem manganese, RRx-001, and MIT-001, are expected to have a positive impact on the oral mucositis treatment landscape, contributing to the expansion of the market.

With a limited number of specific treatments available for oral mucositis, there is significant potential for the development of novel therapies, which will help further drive the growth of the oral mucositis market.

Oral Mucositis Therapy Assessment

GC4419: Galera Therapeutics

GC4419, also known as avasopasem manganese, has successfully completed two clinical trials in which it was evaluated for reduction of severe oral mucositis in patients with head and neck cancer undergoing radiation therapy and also receiving cisplatin, a chemotherapy drug. The drug is currently in phase III stage of clinical trial evaluation to treat Oral Mucositis.

SGX942: Soligenix

SGX942 is unique in its mechanism addressing the underlying innate immune dysfunction that contributes to the severity and duration of mucositis. Administered twice weekly by a brief 4-minute IV infusion during chemoradiation treatment while patients are otherwise present at their clinician's office or hospital, SGX942 may be a clinically convenient and safe approach to mitigating oral mucositis. Company's pivotal Phase 3 clinical study ("DOM-INNATE") for oral mucositis in head and neck cancer patients has completed enrollment.

Oral Mucositis Key Companies

*
Galera Therapeutics

*
Soligenix

*
Izun Pharma

*
MitoImmune Therapeutics

*
Tosk

*
Cellix Bio

*
Enzychem Lifesciences

*
Monopar Therapeutics

Oral Mucositis Pipeline Drugs

*
Brilacidin

*
EC-18

*
Corral System

*
CareMin650

*
Validive (Clonidine Lauriad)

*
MuReva Phototherapy System

*
RRx-001

*
SGX942

*
Vasospasm (GC4419)

*
And many others.

For more information, visit Oral Mucositis Market Analysis, Patient Pool, and Emerging Therapies [https://www.delveinsight.com/report-store/oral-mucositis-om-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]

Scope of the Oral Mucositis Market Report:

*
11 Years Forecast

*
7MM Coverage

*
Descriptive overview of Oral Mucositis, causes, signs and symptoms, diagnosis, treatment

*
Comprehensive insight into Oral Mucositis epidemiology in the 7MM

*
Oral Mucositis marketed and emerging therapies

*
Oral Mucositis companies

*
Oral Mucositis market drivers and barriers

Key Questions Answered in the Oral Mucositis Market Report 2034:

*
What was the Oral Mucositis market share distribution in 2020, and how would it appear in 2034?

*
What is the total Oral Mucositis market size and the market size by therapy across the 7MM for the study period (2020-32)?

*
What are the important findings from 7MM, and which country will have the greatest Oral Mucositis market size from 2020-32?

*
During the study period (2020-2034), at what CAGR is the Oral Mucositis market projected to expand at 7MM?

Table of Contents:

1 Oral Mucositis Market Key Comprehensive Insights

2 Oral Mucositis Market Report Introduction

3 Competitive Intelligence Analysis for Oral Mucositis

4 Oral Mucositis Market Analysis Overview at a Glance

5 Executive Summary of Oral Mucositis

6 Oral Mucositis Epidemiology and Market Methodology

7 Oral Mucositis Epidemiology and Patient Population

8 Oral Mucositis Patient Journey

9 Oral Mucositis Treatment Algorithm, Oral Mucositis Current Treatment, and Medical Practices

10 Key Endpoints in Oral Mucositis Clinical Trials

11 Oral Mucositis Marketed Therapies

12 Oral Mucositis Emerging Therapies

13 Oral Mucositis: 7 Major Market Analysis

14 Attribute analysis

15 Access and Reimbursement Overview of Oral Mucositis

16 Oral Mucositis Market Key Opinion Leaders Reviews

18 Oral Mucositis Market Drivers

19 Oral Mucositis Market Barriers

20 SWOT Analysis

21 Disclaimer

22 DelveInsight Capabilities

23 About DelveInsight

Related Reports:

Oral Mucositis Epidemiology 2034

DelveInsight's "Oral Mucositis - Epidemiology Forecast to 2034" report delivers an in-depth understanding of the disease, historical and forecasted Oral Mucositis epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Oral Mucositis Pipeline 2024

"Oral Mucositis Pipeline Insights, 2023" report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Oral Mucositis market. A detailed picture of the Oral Mucositis pipeline landscape is provided, which includes the disease overview and Oral Mucositis treatment guidelines.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=oral-mucositis-market-expected-to-rise-companies-galera-therapeutics-soligenix-izun-pharma-mitoimmune-therapeutics-tosk-cellix-bio-enzychem-lifesciences-monopar-therapeutics]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/



This release was published on openPR.